A commercial radioimmunoassay was adapted to detect serum Dane particle-associated HBeAg in patients whose sera contained the homologous antibody. HBeAg was released from Dane particles with guanidine HC1. Dane particles were separated from anti-HBe by gel-filtration (Sepharose 4B) and ultracentrif
Fulminant hepatitis associated with hepatitis B virus e antigen–negative infection: Importance of host factors
✍ Scribed by Peter Karayiannis; Alexandra Alexopoulou; Stephanos Hadziyannis; Mark Thursz; Richard Watts; Dr Seiji Seito; Howard C. Thomas
- Publisher
- John Wiley and Sons
- Year
- 1995
- Tongue
- English
- Weight
- 723 KB
- Volume
- 22
- Category
- Article
- ISSN
- 0270-9139
No coin nor oath required. For personal study only.
✦ Synopsis
The precore stop-codon variant of hepatitis B v i r u s (HBV) has been implicated in fulminant hepatitis. The precorelcore regions of such variants from two sets of patients with interpartner transmission resulting in fulminant hepatitis in the contact, were sequenced to establish whether further sequence variations in the core region are specifically associated with the fulminant disease. In both sets of patients, there was sequence diversity of the precorelcore region from the wild type, leading to numerous amino acid substitutions in the core region. Between the infecting source and the contact, there was only one amino acid change in one set of patients and none in the other. In addition, in the second set of patients, serum samples from four different time points were investigated. Sequence data showed no variation in each patient at the nucleotide level in the core region, even in the case of the source, who was followed for 3 years. In this same pair of subjects, the remainder of the genome was sequenced and was identical at the nucleotide level. Therefore, it appears that, at least in some cases of fulminant hepatitis caused by infection with the precore variant, the nucleotide sequence of the patient with fulminant hepatitis is identical to that observed in the asymptomatic source of infection. These data indicate that the severity and outcome of infection in such cases are unrelated to any additional variation in the entire HBV genome, and that the changed clinical picture is dependent on host factors, possibly the HLA environment. HLA typing of both the contact and source in the two sets of patients revealed that the contacts Abbreviations: HBV, hepatitis B virus; PCR, polymerase chain reaction; nt, nucleotides.
📜 SIMILAR VOLUMES
This placebo controlled, double-blind study evaluated the efficacy and safety of lamivudine in patients with hepatitis B e antigen (HBeAg)-negative/hepatitis B virus (HBV) DNA-positive chronic hepatitis B. Patients were randomized to receive 100 mg lamivudine orally once daily for 52 weeks (n ؍ 60
## Abstract Antibody to hepatitis B surface antigen (HBsAg) (anti‐HBs) can exist in patients with chronic hepatitis B virus (HBV) infection. To date, little is known about the association of concurrent HBsAg and anti‐HBs (concurrent HBsAg/ anti‐HBs) with hepatocellular carcinoma (HCC). The aim of t
## Abstract Variants in the amino acid composition of the primary antibody‐binding site of hepatitis B surface antigen (HBsAg) have been identified in a number of populations with chronic hepatitis B virus (HBV) infection. Direct sequencing of amplified or cloned PCR products, solid phase detection
## Abstract Changes in serologic status in human immunodeficiency virus (HIV)/hepatitis B virus (HBV) co‐infected individuals with either isolated anti‐HBc or resolved HBV infection have been reported, but the frequency of clinically meaningful long‐term serologic changes is not well‐defined. This